Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) EBT Margin (2016 - 2025)

Historic EBT Margin for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to 8.04%.

  • Anika Therapeutics' EBT Margin fell 91400.0% to 8.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.06%, marking a year-over-year decrease of 360700.0%. This contributed to the annual value of 3.4% for FY2024, which is 60100.0% down from last year.
  • Latest data reveals that Anika Therapeutics reported EBT Margin of 8.04% as of Q3 2025, which was down 91400.0% from 14.05% recorded in Q2 2025.
  • Anika Therapeutics' 5-year EBT Margin high stood at 23.93% for Q2 2021, and its period low was 871.99% during Q4 2023.
  • Moreover, its 5-year median value for EBT Margin was 8.28% (2022), whereas its average is 84.01%.
  • Per our database at Business Quant, Anika Therapeutics' EBT Margin tumbled by -5799200bps in 2022 and then skyrocketed by 8678200bps in 2024.
  • Quarter analysis of 5 years shows Anika Therapeutics' EBT Margin stood at 18.54% in 2021, then crashed by -3128bps to 598.46% in 2022, then tumbled by -46bps to 871.99% in 2023, then skyrocketed by 100bps to 4.17% in 2024, then plummeted by -93bps to 8.04% in 2025.
  • Its last three reported values are 8.04% in Q3 2025, 14.05% for Q2 2025, and 14.79% during Q1 2025.